Repligen Co. (NASDAQ:RGEN) Given Average Recommendation of “Buy” by Analysts

Repligen Co. (NASDAQ:RGENGet Rating) has earned an average recommendation of “Buy” from the eight brokerages that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $285.57.

A number of analysts have weighed in on RGEN shares. Craig Hallum cut their target price on shares of Repligen from $286.00 to $274.00 in a research report on Thursday, April 28th. StockNews.com started coverage on shares of Repligen in a research note on Thursday, March 31st. They set a “hold” rating for the company. Zacks Investment Research downgraded shares of Repligen from a “buy” rating to a “hold” rating and set a $190.00 target price for the company. in a research note on Monday, February 21st. Finally, SVB Leerink dropped their price objective on shares of Repligen from $275.00 to $250.00 and set an “outperform” rating on the stock in a report on Friday, February 18th.

In other Repligen news, Director Thomas F. Ryan, Jr. sold 2,000 shares of the company’s stock in a transaction dated Tuesday, March 1st. The shares were sold at an average price of $198.03, for a total value of $396,060.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.10% of the company’s stock.

Hedge funds have recently modified their holdings of the business. HM Payson & Co. bought a new position in shares of Repligen during the 4th quarter valued at approximately $26,000. Harding Loevner LP grew its position in shares of Repligen by 121.3% during the 1st quarter. Harding Loevner LP now owns 177 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 97 shares during the period. Confluence Wealth Services Inc. bought a new position in shares of Repligen during the 4th quarter valued at approximately $27,000. Cambridge Trust Co. bought a new position in shares of Repligen during the 1st quarter valued at approximately $38,000. Finally, Sageworth Trust Co of South Dakota bought a new position in shares of Repligen during the 4th quarter valued at approximately $46,000. 86.82% of the stock is owned by institutional investors and hedge funds.

NASDAQ RGEN opened at $154.53 on Friday. The firm has a market capitalization of $8.41 billion, a price-to-earnings ratio of 61.08 and a beta of 0.98. The firm’s 50 day simple moving average is $165.24 and its 200 day simple moving average is $204.65. Repligen has a 1 year low of $137.21 and a 1 year high of $327.32.

Repligen (NASDAQ:RGENGet Rating) last issued its earnings results on Wednesday, April 27th. The biotechnology company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.20. Repligen had a net margin of 19.86% and a return on equity of 11.13%. The firm had revenue of $206.40 million for the quarter, compared to analyst estimates of $185.48 million. During the same quarter last year, the business posted $0.68 earnings per share. The company’s quarterly revenue was up 44.5% on a year-over-year basis. Equities research analysts predict that Repligen will post 3.1 earnings per share for the current year.

About Repligen (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.